# Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears

> **NCT02045888** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Cytori Therapeutics**

## Conditions studied

- Muscle Tear

## Interventions

- **DEVICE:** ADRCs prepared by investigational Celution Device
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02045888
- **Lead sponsor:** Cytori Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-01
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn (No Participants Enrolled)
- **Last updated:** 2014-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045888, "Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02045888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*